Physician profile
Devyn Leigh Freeman
NPI 1184352700
$7,194.63
in general payments reported to CMS, 2019-2025
20 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $608 · 2023: $3,278 · 2024: $1,647 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,469 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,468.86 |
| Education | $118.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,525.39 | 2022-2025 | |
| Leo Pharma INC. | $994.80 | 2022-2025 | Adbry, Anzupgo |
| Incyte Corporation | $540.80 | 2022-2025 | Opzelura, Opzelura |
| Dermavant Sciences, INC. | $481.76 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $475.44 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $470.97 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $430.88 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $425.20 | 2022-2025 | Ilumya |
| Pfizer INC. | $401.04 | 2022-2025 | |
| Genzyme Corporation | $373.13 | 2023-2025 | |
| Ucb, INC. | $271.74 | 2022-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $210.78 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $203.48 | 2023-2025 | |
| Amgen INC. | $180.44 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $78.62 | 2024-2025 | Aklief, Nemluvio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $36.17 | 2025 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $33.00 | 2023-2025 | Valchlor |
| Lilly USA, LLC | $22.63 | 2025 | Taltz, Ebglyss |
| Alexion Pharmaceuticals, INC. | $20.57 | 2025 | Koselugo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.79 | 2024 | Arazlo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devyn Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.